New perspectives for the diagnosis of Alzheimer's disease

Recent Patents on CNS Drug Discovery

Volumn 4, Issue 3, 2009, Pages 160-181

  Urbanelli, Lorena ^a   Magini, Alessandro ^a   Ciccarone, Virginia ^a   Trivelli, Francesco ^a   Polidoro, Mario ^a   Tancini, Brunella ^a   Emiliani, Carla ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Alzheimer's disease; Amyloid peptides; Autoantigens; Biomarkers; Cell cycle; CSF; Diagnosis; Fibroblasts; Lymphocytes; Peripheral tissue; Plasma; Proteomics; SELDI; Serum; Tau

Indexed keywords

AD7C NEURONAL THREAD PROTEIN; ALZHEIMER ASSOCIATED PROTEIN; AMINO ACID; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AUTOANTIGEN; BETA SECRETASE; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; BRAIN PROTEIN; FLUORODEOXYGLUCOSE F 18; GLYCOGEN SYNTHASE KINASE 3; GLYCOPROTEIN; HEME OXYGENASE INHIBITOR; ISOPROSTANE DERIVATIVE; MELANOTRANSFERRIN; NECTIN 1; NEU DIFFERENTIATION FACTOR; PEPTIDE; PROTEIN P97; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; BODY FLUID; BRAIN SIZE; CELL ACTIVITY; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE COURSE; ENZYME ACTIVITY; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PEPTIDOMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEOMICS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSCRIPTOMICS;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS;

EID: 70449516060     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488909789104839     Document Type: Review

References (273)

1. Burns A, Iliffe S. Alzheimer's disease. BMJ 2009; 338(158).
2. DeKosky ST, Marek K. Looking backward to move forward: Early detection of neurodegenerative disorders. Science 2003; 302(5646): 830-834.
3. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368(9533): 387-403.
4. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005; 366(9503): 2112-2117.
5. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115(6): 1449-1457.
6. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349(6311): 704-706.
7. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial alzheimer's disease locus. Science 1995; 269(5226): 973-977.
8. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial alzheimer's disease. Nature 1995; 375(6534): 754-760.
9. Meyer MR, Tschanz JT, Norton MC, et al. APOE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease. Nat Genet 1998; 19(4): 321-322.
10. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004; 25(5): 641-650.
11. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278(16): 1349-1356.
12. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261(5123): 921-923.
13. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial alzheimer disease. Proc Natl Acad Sci USA 1993; 90(5): 1977-1981.
14. Hardy J, Selkoe DJ. The amyloid hypothesis of alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002; 297(5580): 353-356.
15. Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120(3): 885-890.
16. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in alzheimer disease and down syndrome. Proc Natl Acad Sci USA 1985; 82(12): 4245-4249.
17. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286(5440): 735-741.
18. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with alzheimer's disease beta-secretase activity. Nature 1999; 402(6761): 533-537.
19. Hussain I, Powell D, Howlett DR, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 1999; 14(6): 419-427. (Pubitemid 30026585)
20. Wolfe MS, Xia W, Ostaszewski BL, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999; 398(6727): 513-517.
21. Iqbal K, Alonso Adel C, Grundke-Iqbal I. Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly. J Alzheimers Dis 2008; 14(4): 365-370.
22. Iqbal K, Alonso Adel C, Chen S, et al. Tau pathology in alzheimer disease and other tauopathies. Biochim Biophys Acta 2005; 1739(2-3): 198-210.
23. Werner P, Korczyn AD. Mild cognitive impairment: Conceptual, assessment, ethical, and social issues. Clin Interv Aging 2008; 3(3): 413-420.
24. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34(7):939-944.
25. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6(8): 734-746.
26. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001; 357(9251):169-175.
27. Godbolt AK, Cipolotti L, Watt H, et al. The natural history of alzheimer disease: A longitudinal presymptomatic and symptomatic study of a familial cohort. Arch Neurol 2004; 61(11):1743-1748.
28. Godbolt AK, Cipolotti L, Anderson VM, et al. A decade of prediagnostic assessment in a case of familial Alzheimer's disease: Tracking progression from asymptomatic to MCI and dementia. Neurocase 2005; 11(1): 56-64.
29. Desikan RS, Fischl B, Cabral HJ, et al. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology 2008; 71(11): 819-825.
30. Schipper H. The role of biological markers in the diagnosis of alzheimer's disease. Alzheimer's Dement 2007; 3: 325-332.
31. DeKosky ST. Taking the next steps in the diagnosis of alzheimer's disease: The use of biomarkers. CNS Spectrosc 2008; 13(3 Suppl 3): 7-10.
32. Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of alzheimer's disease. Neurobiol Dis 2008 [Epub ahead of print].
33. Hampel H, Burger K, Teipel SJ, et al. Core candidate neurochemical and imaging biomarkers of alzheimer's disease. Alzheimers Dement 2008; 4(1): 38-48.
34. Jellinger KA, Janetzky B, Attems J, Kienzl E. Biomarkers for early diagnosis of alzheimer disease: 'ALZheimer ASsociated gene' - a new blood biomarker? J Cell Mol Med 2008; 12(4):1094-1117.
35. Klunk WE. Biological markers of alzheimer's disease. Neurobiol Aging 1998; 19(2):145-147.
36. Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: A shrinking brain. J Neurosci 2003; 23(8): 3295-3301. (Pubitemid 36531970)
37. Fox NC, Schott JM. Imaging cerebral atrophy: Normal ageing to alzheimer's disease. Lancet 2004; 363(9406): 392-394.
38. Chan D, Janssen JC, Whitwell JL, et al. Change in rates of cerebral atrophy over time in early-onset alzheimer's disease: Longitudinal MRI study. Lancet 2003; 362(9390): 1121-1122.
39. Silbert LC, Quinn JF, Moore MM, et al. Changes in premorbid brain volume predict alzheimer's disease pathology. Neurology 2003; 61(4): 487-492.
40. Pennanen C, Kivipelto M, Tuomainen S, et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging 2004; 25(3): 303-310.
41. Jack CR Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005; 65(8): 1227-1231.
42. Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial alzheimer's disease: A serial MRI study. Lancet Neurol 2006; 5(10): 828-834.
43. Barnes LL, Wilson RS, Li Y, et al. Change in cognitive function in alzheimer's disease in African-American and white persons. Neuroepidemiology 2006; 26(1): 16-22.
44. Barnes J, Godbolt AK, Frost C, et al. Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD. Neurobiol Aging 2007; 28(1): 20-28.
45. Whitwell JL, Jack CR Jr. Comparisons between alzheimer disease, frontotemporal lobar degeneration, and normal aging with brain mapping. Top Magn Reson Imaging 2005; 16(6): 409-425.
46. Silverman DH, Mosconi L, Ercoli L, Chen W, Small GW. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med 2008; 38(4): 251-261.
47. De Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001; 98(19):10966-10971.
48. Chetelat G, Eustache F, Viader F, et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 2005; 11(1): 14-25.
49. Mosconi L, De Santi S, Rusinek H, Convit A, De Leon MJ. Magnetic resonance and PET studies in the early diagnosis of alzheimer's disease. Expert Rev Neurother 2004; 4(5): 831-849.
50. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD: Automated FDG-PET image analysis. Neurology 2005; 64(11): 1860-1867.
51. Silverman DH, Phelps ME. Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: Normal development, aging, dementia, and stroke. Mol Genet Metab 2001; 74(1-2): 128-138.
52. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001; 22(4): 529-539.
53. Klunk WE, Engler H, Nordberg A, et al. Imaging the pathology of alzheimer's disease: Amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am 2003; 13(4): 781-789.
54. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55(3): 306-319.
55. Nordberg A. Molecular imaging markers in clinical trials in alzheimer s disease. J Nutr Health Aging 2009; 13(4): 346-347.
56. Nordberg A. The future: New methods of imaging exploration in alzheimer's disease. Front Neurol Neurosci 2009; 24: 47-53.
57. Hampel H, Mitchell A, Blennow K, et al. Core biological marker candidates of alzheimer's disease-perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004; 111(3): 247-272. (Pubitemid 38316604)
58. Shoji M. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness. Front Biosci 2002; 7: d997-1006.
59. Lewczuk P, Esselmann H, Groemer TW, et al. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ ionization time-of-flight mass spectrometry: Evidence of novel biomarkers in alzheimer's disease. Biol Psychiatry 2004; 55 (5): 524-530.
60. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60(4): 652-656.
61. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59(3): 512-519.
62. Kawarabayashi T, Younkin LH, Saido TC, et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of alzheimer's disease. J Neurosci 2001; 21(2): 372-381. (Pubitemid 32107428)
63. Blennow K, Hampel H. CSF markers for incipient alzheimer's disease. Lancet Neurol 2003; 2(10): 605-613.
64. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with alzheimer disease. Neurosci Lett 2001; 304(1-2): 102-106.
65. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurol 2006; 5(8): 655-660.
66. Hansson O, Zetterberg H, Vanmechelen E, et al. Evaluation of plasma abeta(40) and abeta(42) as predictors of conversion to alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2008 [Epub ahead of print].
67. Hartmann, T., Eikenberg, O., Antz, C.: WO03104812 (2003).
68. Wiltfang, J., Lewczuk, P., Kornhuber, J.: WO2004092737 (2004).
69. Vanderstichele, H., Vanmechelen, E., Blennow, K., De Meyer, G., Kostanjevecki, V.: WO2004104197 (2004).
70. Munter LM, Voigt P, Harmeier A, et al. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J 2007; 26(6): 1702-1712.
71. Multhaup, G., Munter, L.M.: WO2007140843 (2007).
72. Jefferies, W.A., Mcgeer, P.L., Rothenberger, S., Food, M.R., Yamada, T., Kennard, M.: US20030077692 (2003).
73. Fitzgerald, G.A., Rokach, J., Pratico, D., Trojanowski, J.Q.: WO00032805 (2000).
74. Vanmechelen, E., Vanderstichele, H., Van De Voorde, A. WO02003073 (2002).
75. Schipper, H.: WO02008449 (2002).
76. Small, D.H., Fodero, L.: WO02059619 (2002).
77. Schrattenholz, A.: WO2004019045 (2004).
78. Lovestone, S.: WO06003414 (2006).
79. Kitazume, S., Oka, R., Hashimoto, Y., Sato, Y.: WO2006121099 (2006).
80. Urakami, K., Kimura, M.: WO2008029886 (2008).
81. Vasan, S., Davidowitz, E.J., Moe, J.G.: WO2008140639 (2008).
82. Federoff, H.J., Lim, S.T.: WO2008148098 (2008).
83. Ladenson, J.H., Laterza, O., Modur, V.: WO2009026432 (2009).
84. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with alzheimer disease. JAMA 2003; 289(16): 2094-2103.
85. Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64(3): 343-349.
86. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999; 52(8): 1555-1562.
87. Burger nee Buch K, Padberg F, Nolde T, et al. Cerebrospinal fluid tau protein shows a better discrimination in young old (70 years) than in old old patients with alzheimer's disease compared with controls. Neurosci Lett 1999; 277(1): 21-24.
88. Andreasen N, Minthon L, Clarberg A, et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999; 53(7): 1488-1494. (Pubitemid 29491942)
89. Hesse C, Rosengren L, Vanmechelen E, et al. Cerebrospinal fluid markers for alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2000; 2(3-4): 199-206. (Pubitemid 32095607)
90. Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and alzheimer's disease. Neurosci Lett 1999; 259(2):133-135.
91. Lee JM, Blennow K, Andreasen N, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of alzheimer disease patients. Clin Chem 2008; 54(10):1617-1623.
92. Lewczuk P, Esselmann H, Bibl M, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in alzheimer's disease: Original data and review of the literature. J Mol Neurosci 2004; 23(1-2): 115-122. (Pubitemid 41359194)
93. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285(1): 49-52.
94. Schoonenboom NS, Pijnenburg YA, Mulder C, et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset alzheimer disease. Neurology 2004; 62(9): 1580-1584.
95. Kurz A, Riemenschneider M, Wallin A. Potential biological markers for cerebrovascular disease. Int Psychogeriatr 2003; 15(Supp l): 89-97.
96. Parnetti L, Lanari A, Saggese E, Spaccatini C, Gallai V. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice. Neurol Sci 2003; 24(3): 199-200.
97. Schonknecht P, Pantel J, Hunt A, et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest alzheimer's disease. Neurosci Lett 2003; 339(2): 172-174.
98. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002; 59 (4): 627-629.
99. Arai H, Ishiguro K, Ohno H, et al. CSF phosphorylated tau protein and mild cognitive impairment: A prospective study. Exp Neurol 2000; 166(1): 201-203.
100. de Leon MJ, DeSanti S, Zinkowski R, et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med 2004; 256(3): 205-223. (Pubitemid 39222990)
101. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 2006; 5(3): 228-234.
102. Lewczuk P, Kornhuber J, Vanderstichele H, et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiol Aging 2008; 29(6):812-818.
103. Zhong Z, Ewers M, Teipel S, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 2007; 64(6):718-726. (Pubitemid 46878672)
104. Ewers M, Zhong Z, Burger K, et al. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and alzheimer's disease. Brain 2008; 131(Pt 5): 1252-1258.
105. Zetterberg H, Andreasson U, Hansson O, et al. Elevated cerebrospinal fluid BACE1 activity in incipient alzheimer disease. Arch Neurol 2008; 65(8): 1102-1107.
106. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in alzheimer's disease. Ann Neurol 2002; 51(6): 783-786.
107. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in alzheimer disease. Arch Neurol 2002; 59(9): 1381-1389.
108. Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: A bio-marker for alzheimer's disease. J Neurol Sci 2006; 240(1-2): 53-58. (Pubitemid 41814953)
109. Padovani A, Pastorino L, Borroni B, et al. Amyloid precursor protein in platelets: A peripheral marker for the diagnosis of sporadic AD. Neurology 2001; 57(12): 2243-2248.
110. Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM. Platelet APP isoform ratios correlate with declining cognition in AD. Neurology 2000; 54(10): 1907-1909.
111. Borroni B, Colciaghi F, Archetti S, et al. Predicting cognitive decline in alzheimer disease. Role of platelet amyloid precursor protein. Alzheimer Dis Assoc Disord 2004; 18(1): 32-34. (Pubitemid 38325893)
112. Borroni B, Colciaghi F, Caltagirone C, et al. Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of alzheimer type: A 2-year follow-up study. Arch Neurol 2003; 60(12):1740-1744.
113. Padovani A, Borroni B, Colciaghi F, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and alzheimer disease. Arch Neurol 2002; 59(1):71-75.
114. Kienzl E, Jellinger K, Janetzky B, Steindl H, Bergmann J. A broader horizon of alzheimer pathogenesis: ALZAS - an early serum biomarker? J Neural Transm Suppl 2002; 62: 87-95.
115. de la Monte SM, Wands JR. The AD7c-ntp neuronal thread protein biomarker for detecting Alzheimer's disease. Front Biosci 2002; 1(7): d989-996.
116. Monte SM, Ghanbari K, Frey WH, et al. Characterization of the AD7C-NTP cDNA expression in alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest 1997; 100(12): 3093-3104. (Pubitemid 28022847)
117. de la Monte SM, Wands JR. Alzheimer-associated neuronal thread protein mediated cell death is linked to impaired insulin signaling. J Alzheimers Dis 2004; 6(3): 231-242.
118. Ghanbari H, Ghanbari K, Beheshti I, et al. Biochemical assay for AD7C-NTP in urine as an alzheimer's disease marker. J Clin Lab Anal 1998; 12(5): 285-288. (Pubitemid 28462315)
119. Levy S, McConville M, Lazaro GA, Averback P. Competitive ELISA studies of neural thread protein in urine in alzheimer's disease. J Clin Lab Anal 2007; 21(1): 24-33. (Pubitemid 46648345)
120. Ghanbari K, Ghanbari HA. A sandwich enzyme immunoassay for measuring AD7C-NTP as an alzheimer's disease marker: AD7C test. J Clin Lab Anal 1998; 12(4): 223-226. (Pubitemid 28304456)
121. Munzar M, Levy S, Rush R, Averback P. Clinical study of a urinary competitve ELISA for neural thread protein in alzheimer disease. Neurol Clin Neurophysiol 2002; 2002(1): 2-8.
122. Kennard ML, Feldman H, Yamada T, Jefferies WA. Serum levels of the iron binding protein p97 are elevated in alzheimer's disease. Nat Med 1996; 2 (11): 1230-1235.
123. Kim DK, Seo MY, Lim SW, et al. Serum melanotransferrin, p97 as a biochemical marker of alzheimer's disease. Neuropsychopharmacology 2001; 25 (1): 84-90. (Pubitemid 32493824)
124. Desrosiers RR, Bertrand Y, Nguyen QT, et al. Expression of melanotransferrin isoforms in human serum: Relevance to Alzheimer's disease. Biochem J 2003; 374 (Pt 2): 463-471.
125. Karkan D, Pfeifer C, Vitalis TZ, et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS ONE 2008; 3(6): e2469.
126. Moreira PI, Smith MA, Zhu X, et al. Oxidative stress and neurodegeneration. Ann N Y Acad Sci 2005; 1043:545-552.
127. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early alzheimer's disease. J Neurosci Res 2007; 85(14): 3036-3040. (Pubitemid 350057358)
128. Pratico D, Lee VMY, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB J 1998; 12(15): 1777-1783. (Pubitemid 28553673)
129. Pratico D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of alzheimer disease. Arch Neurol 2002; 59(6): 972-976.
130. Montine TJ, Quinn JF, Milatovic D, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in alzheimer's disease. Ann Neurol 2002; 52(2): 175-179.
131. Morrow JD. The isoprostanes-unique products of arachidonate peroxidation: Their role as mediators of oxidant stress. Curr Pharm Des 2006; 12(8): 895-902.
132. de Leon MJ, DeSanti S, Zinkowski R, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006; 27(3): 394-401.
133. Greco A, Minghetti L, Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res 2000; 25(9-10): 1357-1364.
134. Schipper HM, Chertkow H, Mehindate K, et al. Evaluation of heme oxygenase-1 as a systemic biological marker of sporadic AD. Neurology 2000; 54(6): 1297-1304.
135. Ishizuka K, Kimura T, Yoshitake J, et al. Possible assessment for antioxidant capacity in alzheimer's disease by measuring lymphocyte heme oxygenase-1 expression with real-time RT-PCR. Ann N Y Acad Sci 2002; 977:173-178.
136. Schipper HM, Mawal Y, Chertkow H, Bergman H. Blood HO-1 mRNA in AD and MCI. Neurology 2001; 57(11): 2142-2143.
137. Maes OC, Kravitz S, Mawal Y, et al. Characterization of alpha1-antitrypsin as a heme oxygenase-1 suppressor in alzheimer plasma. Neurobiol Dis 2006; 24(1): 89-100.
138. Guevara J, Espinosa B, Zenteno E, et al. Altered glycosylation pattern of proteins in alzheimer disease. J Neuropathol Exp Neurol 1998; 57(10): 905-914. (Pubitemid 28478001)
139. McFarlane I, Georgopoulou N, Coughlan CM, Gillian AM, Breen KC. The role of the protein glycosylation state in the control of cellular transport of the amyloid beta precursor protein. Neuroscience 1999; 90(1): 15-25.
140. Ozaki M, Sasner M, Yano R, Lu HS, Buonanno A. Neuregulin-beta induces expression of an NMDA-receptor subunit. Nature 1997; 390(6661): 691-694.
141. Takai Y, Nakanishi H. Nectin and afadin: novel organizers of intercellular junctions. J Cell Sci 2003; 116(Pt 1): 17-27. (Pubitemid 36113961)
142. Gasparini L, Racchi M, Binetti G, et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing alzheimer's disease. FASEB J 1998; 12(1): 17-34.
143. Etcheberrigaray R, Ito E, Oka K, et al. Potassium channel dysfunction in fibroblasts identifies patients with alzheimer disease. Proc Natl Acad Sci USA 1993; 90(17): 8209-8213.
144. Hirashima N, Etcheberrigaray R, Bergamaschi S, et al. Calcium responses in human fibroblasts: A diagnostic molecular profile for alzheimer's disease. Neurobiol Aging 1996; 17(4): 549-555.
145. Etcheberrigaray, R., Bhagavan, S., Bank, B., Alkon, D.: WO01077686 (2001).
146. Zhao, W.Q., Alkon, D.L.: WO2006054979 (2006).
147. Khan, T.K., Alkon, D.L.: WO2007047029 (2007)
148. Zhao WQ, Ravindranath L, Mohamed AS, et al. MAP kinase signaling cascade dysfunction specific to alzheimer's disease in fibroblasts. Neurobiol Dis 2002; 11(1): 166-183.
149. Khan TK, Alkon DL. Early diagnostic accuracy and pathophysiologic relevance of an autopsy-confirmed alzheimer's disease peripheral biomarker. Neurobiol Aging 2008 [Epub ahead of print].
150. Nagy Z, Combrinck M, Budge M, McShane R. Cell cycle kinesis in lymphocytes in the diagnosis of alzheimer's disease. Neurosci Lett 2002; 317(2): 81-84.
151. Nagy, Z.: WO02073212 (2002).
152. Nagy, Z.: WO02073212 (2002)
153. Arendt, T., Stieler, J.: WO2005050219 (2005).
154. Wands, J.R., De La Monte, S.M.: WO2007123723 (2007).
155. Arendt, T., Gartner, W.J., Grimes, F.R., Stieler, J., Weber, D.F.: WO2008003516 (2008).
156. Holzer M, Gartner U, Klinz FJ, et al. Activation of mitogen-activated protein kinase cascade and phosphorylation of cytoskeletal proteins after neurone-specific activation of p21ras. I. mitogen-activated protein kinase cascade. Neuroscience 2001; 105(4): 1031-1040. (Pubitemid 32786815)
157. Holzer M, Rodel L, Seeger G, et al. Activation of mitogen-activated protein kinase cascade and phosphorylation of cytoskeletal proteins after neurone-specific activation of p21ras. II. Cytoskeletal proteins and dendritic morphology. Neuroscience 2001; 105(4): 1041-1054.
158. De la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to alzheimer's disease. J Alzheimers Dis 2005; 7(1): 45-61. (Pubitemid 40387184)
159. Carro E, Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of alzheimer's disease. Eur J Pharmacol 2004; 490(1-3): 127-133. (Pubitemid 38482166)
160. Schubert M, Brazil DP, Burks DJ, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003; 23(18): 7084-7092. (Pubitemid 36975873)
161. Schubert M, Gautam D, Surjo D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 2004; 101(9): 3100-3105.
162. Mendonsa G, Dobrowolska J, Lin A, et al. Molecular profiling reveals diversity of stress signal transduction cascades in highly penetrant alzheimer's disease human skin fibroblasts. PLoS ONE 2009; 4 (2): e4655.
163. Khan TK, Nelson TJ, Verma VA, Wender PA, Alkon DL. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts. Neurobiol Dis 2009; 34(2): 332-339.
164. Cataldo AM, Mathews PM, Boiteau AB, et al. Down syndrome fibroblast model of alzheimer-related endosome pathology: Accelerated endocytosis promotes late endocytic defects. Am J Pathol 2008; 173(2): 370-384.
165. Urbanelli L, Emiliani C, Massini C, et al. Cathepsin D expression is decreased in alzheimer's disease fibroblasts. Neurobiol Aging 2008; 29(1): 12-22.
166. Emiliani C, Urbanelli L, Racanicchi L, et al. Up-regulation of glycohydrolases in alzheimer's disease fibroblasts correlates with Ras activation. J Biol Chem 2003; 278(40): 38453-38460. (Pubitemid 37221739)
167. Nagasaka Y, Dillner K, Ebise H, et al. A unique gene expression signature discriminates familial alzheimer's disease mutation carriers from their wild-type siblings. Proc Natl Acad Sci USA 2005; 102(41): 14854-14859.
168. Cashman JR, Ghirmai S, Abel KJ, Fiala M. Immune defects in alzheimer's disease: New medications development. BMC Neurosci 2008; 9(Suppl 2): S13.
169. Britschgi M, Wyss-Coray T. Systemic and acquired immune responses in alzheimer's disease. Int Rev Neurobiol 2007; 82: 205-233.
170. Mor F, Izak M, Cohen IR. Identification of aldolase as a target antigen in alzheimer's disease. J Immunol 2005; 175(5):3439-3445. (Pubitemid 41170568)
171. Mor, F., Izak, M., Cohen, I.R.: WO2006067792 (2006).
172. Zinkowski, R.P., Kerkman, D.J., Kohnken, R.E., Debernardis, J.F., Davies, P.: US20080181883 (2008).
173. Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ. A68: A major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991; 251(4994): 675-678.
174. Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 1998; 4(7): 832-834.
175. Wiltfang, J., Korn-Huber, J., Henkel, A.W., Lewczuk, P., Klafki, H.W.: WO2007082750 (2007).
176. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis. J Neuroimmunol 2000; 107 (2):161-166. (Pubitemid 30347422)
177. Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of alzheimer disease: The Framingham Study. Neurology 2007; 68(22): 1902-1908.
178. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: The rotterdam study. Arch Neurol 2004; 61(5): 668-672.
179. Akiyama H, Barger S, Barnum S, et al. Inflammation and alzheimer's disease. Neurobiol Aging 2000; 21(3): 383-421.
180. Akiyama H, Arai T, Kondo H, et al. Cell mediators of inflammation in the alzheimer disease brain. Alzheimer Dis Assoc Disord 2000; 14(Suppl 1): S47-53.
181. Balin, B.J., Abrams, J.T., Hudson, A.P., Whittum-Hudson, J.A.: US20070135360 (2007).
182. Ray, S., Wyss-coray, A.: WO2006133423 (2006).
183. Scacchi R, Ruggeri M, Gambina G, et al. Plasma alpha 1-antichymotrypsin in alzheimer's disease; relationships with APOE genotypes. Neurobiol Aging 2001; 22(3): 413-416. (Pubitemid 32510913)
184. Hinds TR, Kukull WA, Van Belle G, et al. Relationship between serum alpha 1-antichymotrypsin and alzheimer's disease. Neurobiol Aging 1994; 15(1): 21-27.
185. Lieberman J, Schleissner L, Tachiki KH, Kling AS. Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol Aging 1995; 16(5): 747-753.
186. Licastro F, Masliah E, Pedrini S, Thal LJ. Blood levels of alpha-1-antichymotrypsin and risk factors for alzheimer's disease: Effects of gender and apolipoprotein E genotype. Dement Geriatr Cogn Disord 2000; 11(1): 25-28.
187. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with alzheimer's disease: Peripheral inflammation or signals from the brain? J Neuroimmunol 2000; 103(1): 97-102. (Pubitemid 30677873)
188. DeKosky ST, Ikonomovic MD, Wang X, et al. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in alzheimer's disease: Correlation with cognitive impairment. Ann Neurol 2003; 53(1): 81-90.
189. Nielsen HM, Minthon L, Londos E, et al. Plasma and CSF serpins in alzheimer disease and dementia with Lewy bodies. Neurology 2007; 69(16): 1569-1579.
190. Flirski M, Sobow T. Biochemical markers and risk factors of alzheimer's disease. Curr Alzheimer Res 2005; 2(1): 47-64.
191. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13(11): 1359-1362.
192. Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161(4): 618-625. (Pubitemid 20120216)
193. Ho L, Guo Y, Spielman L, et al. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for alzheimer's disease assessed by DNA microarray technique. Neurosci Lett 2001; 298(3): 191-194.
194. Colangelo V, Schurr J, Ball MJ, et al. Gene expression profiling of 12633 genes in alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002; 70(3): 462-473. (Pubitemid 35222383)
195. Hata R, Masumura M, Akatsu H, et al. Up-regulation of calcineurin Abeta mRNA in the alzheimer's disease brain: Assessment by cDNA microarray. Biochem Biophys Res Commun 2001; 284(2): 310-316.
196. Schweighoffer, F., Bracco, L.: WO2007132120 (2007).
197. Lovell, M.A., Lynn, B.C.: US20080026405 (2008).
198. Bergmann, A., Fischer-Schulz, C., Struck, J.: US2008248509 (2008).
199. Rosell Vives, E., M., Ferrer Abizanda, I., Maes, T.: US2008318220 (2008).
200. Rosell Vives, E., Barrachina Castillo, M., Ferrer Abizanda, I., Maes, T.: US2008318221 (2008).
201. Durham K.L., Friedman, D.L., Herath, H.M.A.C., Kimmel, L.H., Parekh, R.B., Potter, D.M., Rohlff, C., Silber, M.B., Snyder, P.J., Soares, H.D., Stiger, T.R., Sunderland, T.P., Townsend, R.R., White, F.W., Williams, S.A.: WO03028543 (2003).
202. Yalkinoglu, O., Konig, G., Hochstrasser, D.F., Sanchez J.C., Carrette, O.: WO2004019043 (2004).
203. Davies, H.A., Mcguire, J., Simonsen, A.H., Blennow, K. Podust, V.: WO2005047484 (2005).
204. Baussant, T., Bougueleret, L., Cusin, I., Mahe, E., Niknejad, A. Reffas, S.: WO2006029838 (2006).
205. Westbrook J., Byers, H., Ward, M., Lovestone, S., Hye, A., Lynham, S., Joubert, R., Prefot, P., Kuhn, K., Baumann, C., Schaefer, J., Prinz, T., Kienle, S.: WO2006035237 (2006).
206. Davies, H.A., Blennow, K., Mcguire, J.N., Podust, V.N., Simonsen, A.H.: WO2006113289 (2006).
207. Davies, H.A., Blennow, K., Mcguire, J., Podust, V., Simonsen, A.H.: WO2006138325 (2006).
208. Verdier, J.M.: WO2007042897 (2007).
209. Devanarayan, V., Modur, V., Seeburger, J.L., Romano, G.J., Simon, A.J., Tanaka, W.K., Laterza, O.: WO2007136614 (2007).
210. Hendrickson, R.C., Seeburger, J.L., Wiener, M., Yates, N.A., Song, Q., Liaw, A.: WO2007139777 (2007).
211. Fonteh, A.N., Harrington, M.G.: WO2008021515 (2008).
212. Kang, S.W., Choi, C.H., Kwon, J.B., Jeong, Y., Lee, J.S., Jiang, J.S., Shin, J.W.: WO2009014342 (2009).
213. Issaq H, Veenstra T. Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE): advances and perspectives. Biotechniques 2008; 44(5): 697-698, 700. (Pubitemid 351656291)
214. Roesli C, Elia G, Neri D. Two-dimensional mass spectrometric mapping. Curr Opin Chem Biol 2006; 10(1): 35-41.
215. Fung ET, Enderwick C. ProteinChip clinical proteomics: Computational challenges and solutions. Biotechniques 2002; (Suppl 34-38): 40-131
216. Tao SC, Chen CS, Zhu H. Applications of protein microarray technology. Comb Chem High Throughput Screen 2007; 10(8): 706-718.
217. Duncan MW, Roder H, Hunsucker SW. Quantitative matrix-assisted laser desorption/ionization mass spectrometry. Brief Funct Genomic Proteomic 2008; 7(5): 355-370.
218. Smith RD. Future directions for electrospray ionization for biological analysis using mass spectrometry. Biotechniques 2006; 41(2): 147-148.
219. Wright GL Jr. SELDI proteinchip MS: A platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002; 2(6): 549-563.
220. Fountoulakis M. Application of proteomics technologies in the investigation of the brain. Mass Spectrom Rev 2004; 23(4): 231-258.
221. Sowell RA, Owen JB, Butterfield DA. Proteomics in animal models of alzheimer's and parkinson's diseases. Ageing Res Rev 2009; 8(1): 1-17.
222. Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM. Genetics, transcriptomics, and proteomics of alzheimer's disease. J Clin Psychiatry 2006; 67(4): 652-670. (Pubitemid 43764244)
223. De Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM. Current state and future directions of neurochemical biomarkers for alzheimer's disease. Clin Chem Lab Med 2007; 45(11): 1421-1434.
224. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007; 6 (4):295-303.
225. Sonnen JA, Keene CD, Montine KS, et al. Biomarkers for alzheimer's disease. Expert Rev Neurother 2007; 7(8): 1021-1028.
226. Zhang J, Montine TJ. Proteomic discovery of CSF biomarkers for alzheimer's disease. Ann Neurol 2007; 61(5): 497; author reply 497-498.
227. Shi M, Caudle WM, Zhang J. Biomarker discovery in neurodegenerative diseases: A proteomic approach. Neurobiol Dis 2008; Supl 26.
228. Aluise CD, Sowell RA, Butterfield DA. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of alzheimer's disease. Biochim Biophys Acta 2008; 1782(10): 549-558.
229. Puchades M, Hansson SF, Nilsson CL, et al. Proteomic studies of potential cerebrospinal fluid protein markers for alzheimer's disease. Brain Res Mol Brain Res 2003; 118(1-2): 140-146.
230. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed alzheimer's disease and non-demented elderly subjects. Neurol Res 2006; 28(2): 155-163.
231. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for alzheimer's disease. Ann Neurol 2007; 61(2): 120-129.
232. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006; 9(3): 293-348. (Pubitemid 44253348)
233. Zhang J, Goodlett DR, Quinn JF, et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 2005; 7(2): 125-133; discussion 173-180. (Pubitemid 40592186)
234. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes alzheimer and parkinson diseases. Am J Clin Pathol 2008; 129(4): 526-529. (Pubitemid 352029270)
235. Wiener MC, Sachs JR, Deyanova EG, Yates NA. Differential mass spectrometry: A label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. Anal Chem 2004; 76(20): 6085-6096.
236. Simonsen AH, McGuire J, Podust VN, et al. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging 2008; 29(7): 961-968.
237. Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of alzheimer's disease. Proteomics 2003; 3(8): 1486-1494.
238. Davies, H.A., Blennow, K., Mcguire, J., Podust, V., Simonsen, A.H. WO2006138325 (2006).
239. Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006; 129(Pt 11): 3042-3050.
240. German DC, Gurnani P, Nandi A, et al. Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed Pharmacother 2007; 61(7): 383-389.
241. Lopez MF, Mikulskis A, Kuzdzal S, et al. High-resolution serum proteomic profiling of alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 2005; 51(10): 1946-1954. (Pubitemid 41368194)
242. Marshall J, Jankowski A, Furesz S, et al. Human serum proteins preseparated by electrophoresis or chromatography followed by tandem mass spectrometry. J Proteome Res 2004; 3(3): 364-382. (Pubitemid 39207340)
243. Zhang R, Barker L, Pinchev D, et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004; 4(1): 244-256.
244. Jackowski, G., Marshall, J.: WO03045991 2003.
245. Jackowski, G., Marshall, J.: WO03046003 (2003).
246. Jackowski, G., Marshall, J.: WO03046564 (2003).
247. Jackowski, G., Marshall, J.: WO03046565 (2003).
248. Jackowski, G., Marshall, J.: WO03566 (2003).
249. Jackowski, G., Marshall, J.: WO03046567 (2003).
250. Jackowski, G., Marshall, J.: WO03046568 (2003).
251. Kosan C, Kunz J. Identification and characterisation of the gene TWIST NEIGHBOR (TWISTNB) located in the microdeletion syndrome 7p21 region. Cytogenet Genome Res 2002; 97 (3-4):167-170. (Pubitemid 37485355)
252. Jackowski, G., Marshall, J.: WO03046569 (2003).
253. Jackowski, G., Marshall, J.: WO03046570 (2003).
254. Jackowski, G., Marshall, J.: WO03046471 (2003).
255. Jackowski, G., Marshall, J.: WO03046572 (2003).
256. Jackowski, G., Marshall, J.: WO03046576 (2003).
257. Jackowski, G., Marshall, J.: WO03054014 (2003).
258. Jackowski, G., Marshall, J.: WO03054547 (2003).
259. Jackowski, G., Marshall, J.: WO03087835 (2003).
260. Jackowski, G., Marshall, J.: WO2004027429 (2004).
261. Berntenis, N., Bohrmann, B., Guentert, A., Mueller, B.: WO2007140971 (2007).
262. Berntenis, N., Bohrmann, B., Guentert, A., Mueller, B.: WO2007140972 (2007).
263. Berntenis, N., Bohrmann, B., Guentert, A., Mueller, B.: WO2007140973 (2007).
264. Berntenis, N., Bohrmann, B., Guentert, A., Mueller, B.: WO2007140974 (2007).
265. Berntenis, N., Bohrmann, B., Guentert, A., Mueller, B.: WO2007140975 (2007).
266. Berntenis, N., Bohrmann, B., Guentert, A., Mueller, B.: WO2007140976 (2007).
267. Berntenis, N., Bohrmann, B., Guentert, A., Mueller, B.: WO2007140977 (2007).
268. Berndt, P., Bohrmann, B.: WO2008148488 (2008).
269. Berndt, P., Bohrmann, B.: WO2008148489 (2008).
270. Berndt, P., Bohrmann, B.: WO2008148490 (2008).
271. Berndt, P., Bohrmann, B.: WO2008148491 (2008).
272. Berndt, P., Bohrmann, B.: WO2008148492 (2008).
273. Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG. Free amino acid and dipeptide changes in the body fluids from alzheimer's disease subjects. Amino Acids 2007; 32(2): 213-224